Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02394587
Other study ID # Pro00052848
Secondary ID F31NR014954-01
Status Completed
Phase N/A
First received February 9, 2015
Last updated December 27, 2017
Start date April 2015
Est. completion date January 2016

Study information

Verified date April 2017
Source Duke University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Significance: The purpose of this exploratory study is to test the feasibility, accessibility, and effects of a mindfulness-based stress reduction program (MBSR) on reducing pain catastrophizing in persons with sickle cell disease (SCD) and chronic pain. One of the most difficult symptoms for SCD patients to manage is chronic pain. Approximately one-third of SCD patients experience chronic pain, which is associated with pain catastrophizing. Pain catastrophizing is a negative mental state toward pain stimuli and pain experience, and is associated with increased pain severity, pain interference, and lower social functioning, physical functioning, and mental health. There have been no psychobehavioral intervention studies that have attempted to alter the experience of pain catastrophizing in persons with SCD. MBSR is a complementary group-based therapy that emphasizes nonjudgmental awareness of thoughts, feelings, and bodily sensations. With no pharmacological or non-pharmacological treatment for catastrophizing in persons with SCD, MBSR offers a potential solution to this highly significant problem for both SCD patients and providers. This project will be the first randomized controlled trial (RCT) of MBSR to reduce pain catastrophizing, and improve quality of life for SCD patients with chronic pain.

Methods: This study will enroll 60 adult patients with SCD and chronic pain from the Duke Adult Sickle Cell Clinic. Patients will be randomized to a MBSR or wait-listed control group. The MBSR group will complete a 6- week, group-based telephonic MBSR program that is administered by a certified MBSR clinician once a week for 90 minutes. MBSR feasibility, acceptability, and effects on pain catastrophizing will be assessed by questionnaires at baseline, week 1, 3, and 6 in both groups. At the end of week 6, 10 randomly selected MBSR participants will complete semi-scripted telephone interviews to help assess intervention acceptability, and the wait-listed control condition will be offered the same MBSR intervention.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date January 2016
Est. primary completion date January 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Provide written informed consent,

2. Are >age 21,

3. Self-identify (to the PI at baseline assessment) that they are experiencing chronic, non-cancer pain that has persisted on most days for more than 6 months, and adversely affects their function or well-being,

4. are able to speak and read English,

5. Have access to a telephone (or cell phone) in the home for the intervention and individual assessment interviews (data from the SCD clinic indicate 82% of patients have a cell phone),

6. Have access to a CD or mp3 player for homework assignments and daily practice,

7. Are available during the scheduled telephone intervention, and

8. Complete and return the baseline assessment

Exclusion Criteria:

- Patients will be excluded if they report previously studying MBSR, currently receiving mindfulness-based or cognitive behavioral therapies, or being regular practitioners of mindfulness, including yoga.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Mindfulness-based Stress Reduction
A non-pharmacological approach to pain management.

Locations

Country Name City State
United States Duke University School of Nursing Durham North Carolina

Sponsors (3)

Lead Sponsor Collaborator
Duke University National Institute of Nursing Research (NINR), National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Acceptability of MBSR as measured by semi-scripted telephone assessments Acceptability of the intervention will be assessed by semi-scripted telephone or in-person interviews. The semi-scripted interview will focus on MBSR patients' reflections and expectations of the program, the mindfulness skills they found useful and in what ways, the skills they found less useful and or difficult to implement, and on any changes in thoughts or actions that resulted from the application of the MBSR techniques. 6 weeks
Primary Feasibility of MBSR as measured by recruitment, attrition rates, and practice logs Feasibility of the intervention will be assessed by recruitment and attrition rates, number of daily mindfulness logs completed, and average number of weekly minutes of mindfulness practice as recorded in logs. Feasibility data will be obtained for both the intervention and control subjects who elect to receive the intervention after the intervention is complete with the MBSR group. However, data will not be analyzed together because the delay to receiving the intervention would affect the results. Data from the control group will be used to help inform future studies. 6 weeks
Secondary Change in Pain Catastrophizing as measured by the Pain Catastrophizing Scale Descriptive statistics will be used to summarize the pain catastrophizing at week1, 3, and 6, as measured by the Pain Catastrophizing Scale. Trajectory analyses, using a type of mixed effects model known as a random coefficients regression model for repeated measurement, will be conducted to evaluate and compare the rate and pattern of change over the 6 weeks in the MBSR and wait-listed control groups for pain catastrophizing. baseline, week 1, week 3, and week 6
Secondary Change in Mindfulness as measured by the Mindful Attention Awareness Scale Descriptive statistics will be used to summarize mindfulness at week1, 3, and 6, as measured by the Mindful Attention Awareness Scale. Trajectory analyses, using a type of mixed effects model known as a random coefficients regression model for repeated measurement, will be conducted to evaluate and compare the rate and pattern of change over the 6 weeks in the MBSR and wait-listed control groups for pain catastrophizing. baseline, week 1, week 3, and week 6
See also
  Status Clinical Trial Phase
Recruiting NCT06078696 - Siplizumab for Sickle Cell Disease Transplant Phase 1/Phase 2
Completed NCT04134299 - To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease N/A
Completed NCT02561312 - Comparison of Two Methods of Transfusion for Stroke Prevention in Sickle Cell
Completed NCT00890396 - Long-Term Effects of Hydroxyurea in Children With Sickle Cell Anemia (The BABY HUG Follow-up Study)
Completed NCT00059293 - Transcranial Doppler (TCD) Ultrasound of Subjects Enrolled in BABY HUG - Ancillary to BABY HUG
Terminated NCT00034528 - Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia Phase 2
Completed NCT00005277 - Cooperative Study of The Clinical Course of Sickle Cell Disease N/A
Active, not recruiting NCT04170348 - Daily Vitamin D for Sickle-cell Respiratory Complications Phase 2
Completed NCT04584528 - Implementing an Individualized Pain Plan (IPP) for ED Treatment of VOE's in Sickle Cell Disease N/A
Recruiting NCT02286154 - Therapeutic Response Evaluation and Adherence Trial (TREAT) N/A
Completed NCT02857023 - Feasibility and Efficacy of a Home-based, Computerized Cognitive Training Program in Pediatric Sickle Cell Disease N/A
Withdrawn NCT01925001 - Phase 2 Study of MP4CO to Treat Vaso-occlusive Sickle Crisis Phase 2
Terminated NCT00122980 - Stroke With Transfusions Changing to Hydroxyurea Phase 3
Completed NCT00246077 - Quality of Life of Children With Sickle Cell Disease Who Are Getting Chronic Transfusions With a Lifeport N/A
Completed NCT00094887 - Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises Phase 2
Completed NCT00035763 - Pain in Sickle Cell Epidemiologic Study N/A
Terminated NCT04091737 - CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease Phase 1
Completed NCT00005300 - Investigation of Selected Patient Groups From The Cooperative Study of Sickle Cell Disease N/A
Recruiting NCT04351698 - SMILES: Study of Montelukast in Sickle Cell Disease Phase 2/Phase 3
Not yet recruiting NCT06290401 - A Socio-ecological Approach for Improving Self-management in Adolescents With SCD Phase 2